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OsteomimicryThe present study was undertaken to clarify the function(s) of Endothelin-1 and its receptors ETAR and ETBR in
osteolytic-bone metastasis from breast cancer, and their regulation by hepatocyte and transforming growth fac-
tors (HGF, TGF-β) and hypoxia. The aimwas to evaluate the adaptability of bonemetastasis tomicroenvironmen-
tal stimuli through Endothelin-1-mediated epithelial-mesenchymal transition (EMT), or the reverse process
MET, and through osteomimicry possible key features for bone colonization. We compared low (MCF-7) and
high (MDA-MB231) invasive-breast carcinoma cells, and 1833-bone metastatic clone, with human pair-
matched primary breast-carcinomas and bone metastases. Parental MDA-MB231 and the derived 1833-clone
responded oppositely to the stimuli. In 1833 cells, TGF-β and hypoxia increased Endothelin-1 release, altogether
reducing invasiveness important for engraftment, while Endothelin-1 enhanced MDA-MB231 cell invasiveness.
The Endothelin-1-autocrine loop contributed to the cooperation of intracellular-signaling pathways and extracel-
lular stimuli triggeringMET in 1833 cells, and EMT inMDA-MB231 cells. Only in 1833 cells, HGF negatively inﬂu-
enced transactivation and release of Endothelin-1, suggesting a temporal sequence of these stimuliwith an initial
role of HGF-triggered Wnt/β-catenin pathway in metastatization. Then, Endothelin-1/ETAR conferred MET and
osteomimetic phenotypes, with Runt-related transcription factor 2 activation and metalloproteinase 9 expres-
sion, contributing to colonization and osteolysis. Findings with human pair-matched primary ductal carcinomas
and bone metastases gave a translational signiﬁcance to the molecular study. Endothelin-1, ETAR and ETBR cor-
related with the acquisition of malignant potential, because of high expression already in the in situ carcinoma.
These molecular markers might be used as predictive index of aggressive behavior and invasive/metastatic
phenotype.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Advanced breast carcinomas are prone to give metastasis at the skel-
eton, viscera and lymph nodes. Bone metastases can develop also ten
years after surgical removal of the primary tumor, because osteotropic
malignant cells may have a long period of quiescence before secondary
outgrowth [1]. Insights into themolecularmechanisms of organotropism
should be provided to devise new therapies aimed at themetastasis, or at
the metastasis-microenvironment cross-talk [1,2]. Osteomimetic prop-
erties are suggested for breast carcinomas with bone tropism, but the, transforming growth factor β;
in-1; MMP, metalloproteinase;
ceptor; PR, progesterone recep-
-untranslated region
ilano, Dipartimento di Scienze
33 Milano, Italy. Tel.: +39 02
ights reserved.underlying regulatory mechanisms and the relevance for colonization
are still elusive [3–6].
Literature does not indicate whether skeletal metastasis from breast
cancer coopt signaling pathways normally used by host bone, as evi-
denced formetastases colonizing other tissues [7]. In view of the plastic-
ity of the metastatic phenotype [8,9], it is difﬁcult to consider the gene
signature of primary carcinoma the only factor responsible for bone tro-
pism. For example Src, a candidate molecular target for therapy of bone
metastasis, is active in human-primary breast carcinoma and in MDA-
MB231 breast carcinoma cells [10,11]. By in vivo selection of the latter
cell line, Massagué and colleagues isolated the 1833 subpopulation
with enhanced ability to give bone metastasis [12]. In the xenograft
model, prepared with the 1833 clone, Src phosphorylation is regulated
by hepatocyte growth factor (HGF) [13]. Osteolytic bone metastasis is
largely prevented by the concomitant blockade of HGF signaling path-
way and the pleiotropic Src activity [14]. Transforming growth factor
β (TGFβ) is one of the most potent regulators of Endothelin-1 (ET-1)
levels in endothelial cells, through functional cooperation of Smad and
AP-1 transcription factors and the co-activator CREB-binding protein
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loproteinases (MMP) 2 and 9, implicated inmigration and invasion [16].
TGFβ stimulates MMP 13 production in chondrosarcoma cells [17], and
activates IL-11 and connective tissue-derived growth factor in 1833-
bone metastatic cells [12].
The establishment of bone metastasis involves bidirectional interac-
tions between cancer cells and the bone microenvironment [18].
Though bone is a hard calciﬁed tissue, bone marrow is a hospitable
environment per se due to the abundant sinusoids and growth factor/
cytokine networks. After engraftment, the metastatic cells seem to per-
turb the microenvironment and exploit the surrounding cells to their
own ends [13,19].
Of note, many of the permissive metastasis–stroma interactions
depend on growth factor binding to speciﬁc receptors, as reported for
TGFβ and HGF [7]. The impact of growth factor signaling on metastatic
colonization is not limited to a simple proliferation/cell survival advan-
tage at secondary sites, but cell signaling may also lead to malignant
traits such as epithelial-mesenchymal transition (EMT) or the reverse
process MET [7,9,20,21]. Hypoxia is a physical stimulus of tumor micro-
environment that induces EMT in tumors, through distinct mechanisms
including the upregulation of HIF-1α [22,23]. The production of the reg-
ulatory peptide ET-1 is affected by cytokines/growth factors and HIF-1α
contributing, therefore, to EMT [24,25], but the involvement of ET-1 in
the formation of bone metastasis is poorly understood. For the choice
of ET-1 in the present study, we relied on the fact that the activation
of ET-1 axis, formed by the ligand ET-1 and its receptors ETAR and
ETBR, is now recognized as a common mechanism underlying the pro-
gression of various solid tumors, including breast cancer [25]. In fact,
the ET-1 axis in tumor microenvironment regulates cell–cell and cell–
matrix interactions, and immunomodulation [25], and is also involved
in new blood vessel formation [26]. Moreover, chromatin methylation
state affects ET-1 and ETAR expression in bone metastatic cells [27].
Our aim was to clarify the role played by ET-1 in the network of bi-
ological and physical stimuli of bone metastasis microenvironment,
considering its inﬂuence on osteomimetic, invasive and EMT/MET phe-
notypes in conjunctionwith the critical growth factors HGF and TGFβ as
well aswith hypoxia in 1833-bonemetastatic clone, comparedwith pa-
rental MDA-MB231 cells. We examined the regulatory function of ET-1
axis on Runt-related transcription factor 2 (Runx2), typical of osteoblast
phenotype [6], and on theWnt/β-catenin transcription pathway, critical
for bone-metastatic process [13]. In molecular medicine the evaluation
of ET-1 axis components could be important for grading, and to this
end we analyzed human specimens of transformed mammary tissue
at different disease stages till the occurrence of bone metastasis. Since
invasive-ductal carcinomas estrogen receptor (ERα)/progesterone re-
ceptor (PR) positive and epidermal growth factor receptor-2 (HER2)
negative were examined, we evaluated some molecular events in a
comparable MCF-7 cell line.
The elevated expression of ETAR in primary breast carcinoma
associates with reduced disease-free survival time in a subgroup of
patients with a putative favorable prognosis according to classic
prognostic factors, and correlates with poor histological differentia-
tion and incidence of distant metastasis [28]. ET-1, ETAR and ETBR
show variable expression in primary breast carcinoma, which is
positively correlated with ER status, lymphovascular invasion and
inﬂammatory component [28]. Metastatic prostate cancer cells
release ET-1, which stimulates bone formation and inhibits bone
resorption giving osteosclerotic lesions [29].
Here, we add new data demonstrating the central role of ET-1 axis in
the network ofmolecular players for breast-cancermetastatic process. In
1833-bone metastatic cells, the various microenvironmental stimuli dif-
ferently inﬂuenced ET-1 production, and the autocrine/paracrine control
of invasiveness. ET-1 autocrine production also regulated ETAR expres-
sion. In particular, our results indicate that ET-1 activated signaling cas-
cades for osteomimicry, by functioning oppositely with respect to HGF.
Finally, dysplastic lesions remarkably expressed ET-1/ETAR/ETBR,potential markers for the incidence of invasive-ductal carcinomas –
ERα/PR positive and HER2 negative – and predictive index of progres-
sion towards bone metastasis.
2. Materials and methods
2.1. Materials
Recombinant-human HGF, recombinant-human TGFβ1, and human
Endothelin-1 immunoassay (ELISA) were from R&D System (Abingdon,
UK). Human Endothelin-1 Calbiochem®was fromMerck Chemicals Ltd
(Nottingham, UK). BQ-123 was from Enzo Life Sciences (Lausen,
Switzerland). Anti-ETAR, anti-ETBR and anti-Snail antibodies were
from Abcam (Cambridge, UK). Anti-E-cadherin (clone 36) was from
Transduction Laboratories (Bedford, MA, USA). Anti-Endothelin-1/2/3
(H-38), anti-N-cadherin (H-4), and anti-Vimentin (V9) were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-MMP 2 and
anti-MMP 9 were from Cell Signaling Technology (Boston, MA, USA).
Alexa Fluor488 and 568 antibodies were from Molecular Probes
(Eugene, OR, USA).
2.2. Cell lines
Invasive parental MDA-MB231 breast carcinoma cells and the de-
rived 1833-bone metastatic clone were kindly given by Dr. J. Massagué
(Memorial Sloan-Kettering Cancer Center, New York), and cultured as
reported before [13]. The comparative study of transcriptomic proﬁle
of the two cell lines identiﬁes a gene set whose expression pattern is as-
sociated with, and promotes the formation of, metastasis to bone [12].
Non-invasive MCF-7 breast carcinoma cells were from European Cell
Cultures Collection, Salisbury, UK [30].
2.3. ELISA assay
ET-1 was measured in the conditioned medium of cells deprived of
serum for 48 h, and exposed for 24 h to TGFβ1 (5 ng/ml), HGF
(100 ng/ml) or hypoxia, followingmanufacturer's protocol. For hypoxic
stimulation, cells were placed in an incubator chamber that was thor-
oughly ﬂushed with a gas mixture containing 5% CO2, 1% O2 and
nitrogen-balanced.
2.4. Western blot analysis
Total extracts (100 μg of protein), prepared from cells treated with
100 ng/ml HGF, 5 ng/ml TGFβ1 or hypoxia, were examined byWestern
blot and immunoblotted with the indicated antibodies [20]. Densito-
metric analysis was performed after reaction with ECL plus chemilumi-
nescence kit from Thermo Fisher Scientiﬁc (RockFord, IL, USA).
2.5. Immunoﬂuorescence
MDA-MB231 and 1833 cells (4 × 104) on coverslips were exposed
to TGFβ, hypoxia or ET-1. The antibodies used were: anti-Endothelin-1
(1:50), anti-ETAR (1:500), anti-Vimentin (1:50), anti-Snail (1:50) and
anti-E-cadherin (1:5000). Secondary reactions with ﬂuorescent anti-
bodies were performed. The images were collected under Eclipse 80i,
Nikon Fluorescence microscope [20].
2.6. Matrigel-invasion assay and transfection of siRNAETAR
The cells were exposed to TGFβ1 (5 ng/ml) or hypoxia, in the
presence or absence of 1 μM BQ123 [31]: 4-hour inhibitor pre-
treatment and 20-hour treatments were performed. Some cells
were treated with HGF (200 ng/ml) or ET-1 (10 or 50 ng/ml) for
24 h. Matrigel invasion chambers from BD-Biocoat Cellware
(Becton-Dickinson Labware, Bedford, MA, USA) were used to
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(8 × 104 per well) in the upper chambers, in the presence or the ab-
sence of BQ123. Other cells were transfected with 100 nM siRNAET-
AR duplex or siRNAMock (Dharmacon, Lafayette, CO, USA) for 48 h,
using Lipofectamine 2000 (Life Technologies, Zug, Switzerland)
[24]. The transfected cells were counted and used for Matrigel
assay. For all the experiments, migration through Matrigel took
place in medium without fetal bovine serum. After 22 h incubation
in a humidiﬁed tissue culture incubator, non-invading cells were re-
moved from the top, and invading cells were stained with Diff-Quick
(Dade Bering, Switzerland). Ten ﬁelds were randomly selected, and
the number of the cells in each ﬁeld was counted and averaged [9].
Total protein extracts were also prepared from transfected cells
and used for Western blot analysis, to verify the silencing of the
receptor protein.2.7. Plasmids and cell transfection
The cells, seeded in 24-multiwell plates, were transfected with
200 ng/well of the following gene reporters. 1) ET-1 promoter
(−3580/+560, S. Li, Pittsburg, PA, USA); ET-1-promoter frag-
ment (−650/+173) with 3′-untranslated region (3′-UTR) down-
stream (F. Rodriguez-Pascual, Madrid, Spain); ET-1-promoter
fragment without 3′-UTR (−650/+173), that was prepared in our lab-
oratory by removing the 3′-UTR with XbaI followed by cloning into
pGL3-Basic vector [27]. 2) Themultimers for Ets-1-consensus sequence
(5-Ets1) [30], for Hypoxia-responsive element (6-HRE, pGL3PGK6TKp),
for NF-kB-binding sites (3-NFkB), for AP-1-binding sites (4-AP-1), for
TCF-binding sites (6-TCF, TOPFLASH), for Runx2-binding sites (6-OSE,
p6OSE2-Luc) were kindly given by P.J. Ratcliffe (Oxford, UK), M. Hung
(Houston, TX, USA), N. Colburn (Frederick, MD, USA), C.J. Gottardi
(New York, NY, USA), G. Karsenty (New York, NY, USA), respectively.
Equivalent amounts of the corresponding empty vectors were
transfected in the controls. After overnight starvation, 24-hour treat-
ment with 200 ng/ml HGF, 5 ng/ml TGFβ1 or hypoxia was performed.
Some cells, transfected with Runx2 or TOPFLASH expression vector,
were exposed to 50 ng/ml ET-1 in the presence or the absence
of BQ123. As internal control, Renilla luciferase plasmid was co-
transfected, and Fireﬂy/Renilla luciferase activity ratios were calculated
by the software.
The expression vector for Runx2-dominant negative (ΔRunx2) from
O. Broux (Lille, France) [32]was transfected (1 μg/well) in cells exposed
to 50 ng/ml ET-1 for various times, and protein extracts were used in
Western blot assays.2.8. Immunohistochemistry
We analyzed serial sections of human specimens from bone me-
tastasis of breast carcinoma (collected during surgical interventions
at Istituto Ortopedico Galeazzi IRCCS, Milano, Italy), and of pair-
matched primary invasive ductal breast carcinoma (ERα/PR posi-
tive and HER2 negative), as well as from invasive ductal carcinoma
triple negative. All the specimens were furnished with the informed
consent of the patients, in accordance with the Declaration of
Helsinki. The tissue sections were processed as previously reported
[13,20].2.9. Statistical analysis
Luciferase activities, densitometric values and cell invasiveness
values were analyzed by analysis of variance, with P b 0.05 considered
signiﬁcant. Differences from controls were evaluated on original-
experimental data.3. Results
3.1. 1833-bone metastatic clone differed from parental MDA-MB231
cells for ET-1 autocrine production and invasiveness in response to
microenvironmental stimuli
ET-1 undergoes autocrine/paracrine secretion in breast-cancer tis-
sue [25,33]. In 1833-bone metastatic clone, compared to parental
MDA-MB231 cells, we measured ET-1 release in response to biological
and physical stimuli that characterize bone metastasis microenviron-
ment [13,23] (Fig. 1A). In 1833 clone, the release of ET-1 was enhanced
by TGFβ and hypoxia, andwas reduced by HGF. In conditionedmedium
of MDA-MB231 cells, TGFβ and HGF increased the ET-1 amount.
In 1833 cells, TGFβ enhanced the steady-state protein levels of
ET-1 and ETAR for all the observation period. After hypoxia, ET-1
peaked at 16 h, remaining elevated thereafter, and ETAR persistently
augmented (Fig. 1B). ETAR showed multiple bands: the 49–50 kDa
band corresponded to amino acid sequence [27], and the heavier
bands were likely to be glycosylated forms of the receptor [34].
Next, we evaluated the intracellular localization of ET-1 and
ETAR. In starved and control cells, ET-1 and ETAR co-localized
throughout the cell (Fig. 1C). As shown in merge 3, TGFβ gave en-
hancements in cytosolic/perinuclear and nuclear signals of ET-1
and ETAR; hypoxia increased the ET-1/ETAR axis signal mostly in
nuclei.
TGFβ and hypoxia reduced 1833-cell invasiveness throughMatrigel,
which depended on the autocrine ET-1 axis (Fig. 1D). In fact, ETAR
blockade with BQ123 prevented the inhibitory effects of TGFβ and hyp-
oxia. Experiments with siRNAETAR gave similar results, since ETAR
knocking down counteracted TGFβ- or hypoxia-dependent inhibition
of invasiveness (Supplementary Fig. 1B). The latter data supported the
blocking effect of BQ123 on ETAR, and conﬁrmed the involvement of
ET-1-ETAR axis in 1833 invasiveness under the above reported experi-
mental conditions. Noteworthy, the cells were exposed to TGFβ or hyp-
oxia before cell count and seeding on Matrigel-coated ﬁlters, thus
excluding that the reduced number of migrated cells was due to an
inhibitory effect on cell proliferation.
ET-1 and ETAR expression andMatrigel invasion for cells exposed to
HGF are reported in Fig. 2. In 1833 cells, HGF progressively reduced ET-1
and ETAR steady-state protein levels, which on the contrary increased
until 24 h in HGF-treated MDA-MB231 cells (Fig. 2A). As shown in
Fig. 2B, HGF did not modify basal invasiveness of 1833 cells, while de-
creasing (−85%) that of MDA-MB231 cells, in agreement with previous
data [30].
Altogether, the results show opposite patterns of ET-1 release and of
ET-1 protein levels in HGF-treated 1833 and MDA-MB231 cells.
3.2. Role of ET-1 in cell invasiveness and EMT/MET-related gene expression
Due to the fact that some of the examined stimuli increased ET-1
production, we studied the effect of ET-1 on cell invasiveness
(Fig. 3A). Exogenous ET-1 reduced invasiveness of 1833 cells in a
dose-dependent manner. In contrast, ET-1 enhanced MDA-MB231 cell
invasiveness, as reported in the literature [35]. Next, we examined the
protein pattern of a panel of genes related to EMT/MET phenotype in re-
sponse to ET-1 at a dose of 50 ng/ml, which gave themaximal effects on
cell invasiveness. In ET-1-treated 1833 cells, we observed progressive
decreases of MMP 2 (active form), N-cadherin, Vimentin and Snail
while E-cadherin, ETAR and ETBR increased (Fig. 3B). These ﬁndings
led us to suppose that ET-1 triggered a MET phenotype in metastatic
cells. In this condition mimicking paracrine ET-1, the cellular level
of ET-1 was enhanced. In MDA-MB231 cells, 6-h ET-1 tripled MMP 2
(active form) and N-cadherin, and doubled ETBR steady-state protein
levels; Vimentin augmented persistently while Snail increased progres-
sively. E-cadherin level was unaffected by ET-1 persisting at an ex-
tremely low level, in agreement with EMT [9]. Exogenous ET-1 down
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result might be that ET-1 decreased the level of pre-proET-1 mRNA
[36]. In fact, extracellular ET-1 regulates the abundance of ET-1 mRNA
in an ETBR-dependent manner [37].
Under the sameexperimental conditions, we performed immunoﬂu-
orescence experiments to examine the cellular expression of EMT/MET
markers, and to give a morphological evaluation of the two cell types
studied (Fig. 3C). In starved 1833 cells, the EMT markers Vimentin – aFig. 1. TGFβ and hypoxia enhanced Endothelin-1 release, expression and intracellular localizat
of 1833 and MDA-MB231 cells exposed to different stimuli. The experiments have been perfo
value; Δ P b 0.05 versus control value in complete medium. (B) Total extracts prepared from ce
was performed, taking into consideration all the immunoreactive bands in each lane. The numb
trol value. Vinculinwas used for normalization. The images are representative of three independ
probedwith anti-Endothelin-1 (green) and anti-ETAR (red) antibodies. The nuclei were stained
1/ETAR. The images are taken at 400×magniﬁcation, and are representative of experiments per
the presence or the absence of 1 μMBQ123,were used forMatrigel invasion assay. BQ123 is an in
of themembrane after staining. The images are taken at 200×magniﬁcation. Representative ima
ten selected ﬁelds for three independent experiments. *P b 0.05 versus starvation or control vacytoskeletal protein- and Snail – a transcription factor – gave signals
throughout the cell, that decreased after ET-1 treatment; the expression
of E-cadherin adhesion molecule, with a punctate pattern around the
nucleus, increased after ET-1 treatment, in agreement withMET pheno-
type. In fact, ET-1 gave the cells an epithelial shape. Starved MDA-
MB231 cells, showed Vimentin and Snail signals that were enhanced
by ET-1 treatment consistent with EMT and mesenchymal shape of the
cells. These data supported those obtained with Western blot analysis.ion affecting invasiveness. (A) Immunoassay of Endothelin-1 in the conditioned medium
rmed three times. The data are the means ± S.E. *P b 0.05, **P b 0.005 versus starvation
lls exposed to TGFβ or hypoxia were analyzed byWestern blot. Densitometric evaluation
ers at the bottom indicate the fold-variations versus starvation (st) value taken as 1. c, con-
ent experiments. (C) The cellswere exposed to the stimuli for 16 h on coverslips, andwere
with DAPI (blue). Merge 1, Endothelin-1/DAPI; merge 2, ETAR/DAPI; merge 3, Endothelin-
formed in triplicate. Size bar: 45 μm(top panel). (D) Cells treatedwith TGFβ or hypoxia, in
hibitor of the Endothelin-1 receptor ETAR.We counted the invading cells on the lower side
ges are shown, and the numbers at the bottomare themeans ± S.E. of the cells counted in
lue; ○P b 0.05 versus TGF β or hypoxia value.
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microenvironmental stimuli
To clarify some regulatory mechanisms involved in ET-1 production,
we studied the transactivation of ET-1 in response to microenvironmen-
tal stimuli.Molecular analysis of the sequences upstream from the exon 1
in the human ET-1 gene reveals the putative binding sites for transcrip-
tion factors, which are important for cell-type control of ET-1-gene
expression in response to different stimuli. Of note, ET-1 might undergo
not only transcriptional, but also post-transcriptional regulation, via
mRNA degradation exerted by a genetic element present in the 3′-UTR
of the gene, corresponding to position 272–1127 [38,39].
We evaluated the transactivating activity of ET-1 entire (−3580/
+560) and minimal (−650/+173) promoter constructs, as well as
that of the minimal promoter linked to 3′-UTR sequence down-
stream (Fig. 4A). In 1833 cells, HGF reduced the minimal promoter
activity, independent of the 3′-UTR sequence. TGFβ and hypoxia
stimulated the activity of the entire and minimal promoters, respec-
tively (Fig. 4B). Under hypoxia, the 3′-UTR seemed to exert the
known destabilizing effect on the transcript. The basal activity of
the construct containing the 650 bp-3′-UTR was half with respect
to that of Endothelin 0.65Luc (Fig. 4B).
In MDA-MB231 cells, only TGFβ doubled the entire-promoter activ-
ity (Fig. 4C). In this cell line, we did not study hypoxia because HIF-1 is
not functional. In fact, after hypoxia a downregulation of the β-subunit
occurs, even if HIF-1α is induced [20].
Next,we determined the activities of transcription factorswithputa-
tive binding sites on ET-1 promoter (Fig. 4D). We have already pub-
lished the basal absolute values of the gene reporters [20]. In 1833
cells, the activity of Hypoxia responsive element (HRE) was decreasedFig. 2. In 1833 andMDA-MB231 cells, HGF oppositely changed Endothelin-1 and ETAR ex-
pression aswell as invasiveness. (A) Total extracts prepared fromcells exposed toHGFwere
analyzed by Western blot. Densitometric evaluation was performed, taking into consider-
ation all the immunoreactive bands in each lane. The numbers at the bottom indicate the
fold-variations versus 1833 starvation (st) value taken as 1. Vinculin was used for normali-
zation. The images are representative of three independent experiments. (B) HGF-treated
cells were used for Matrigel invasion assay. We counted the invading cells on the lower
side of themembrane after staining. The images are taken at 200×magniﬁcation. Represen-
tative images are shown, and the numbers at the bottom are the means ± S.E. of the cells
counted in ten selected ﬁelds for three independent experiments. ***P b 0.001 versus star-
vation value.by HGF and increased by hypoxia; Ets1 and NF-kB were enhanced by
both HGF and TGFβ; AP-1 was stimulated by TGFβ. In MDA-MB231
cells, Ets1 and NF-kB were reduced by HGF, while TGFβ stimulated
NF-kB.
In 1833 cells, the HIF-1 (CGTT) consensus sequence of ET-1 0.65Luc
seemed principally responsible for the opposite response to HGF and
hypoxia. ET-1 induction after TGFβ seemed due to the activities of
AP-1 – known to cooperate with Smads [15] – of Ets1 and of NF-kB.
Of note, AP-1 activity was unaffected by HGF or hypoxia.
3.4. Opposite effects of ET-1 and HGF on the molecular events which
characterize osteomimicry
We further evaluated the possible signiﬁcance of reduced produc-
tion and expression of ET-1 in HGF-treated 1833 cells, by assaying the
effects of ET-1 and HGF on Runx2 transcription factor, and the gene tar-
getMMP 9 [40], aswell as onWnt pathway (Fig. 5). The luciferase activ-
ity of Runx2 increased (about 4-fold) after ET-1, an effect prevented by
ETAR blockadewith BQ123 (Fig. 5A). In contrast, HGF and TGFβ reduced
Runx2Luc activity (Fig. 5B). The activity of TOPFLASHLuc decreased after
ET-1 as well as after BQ123, and these inhibitory effects were additive
(Fig. 5C). An implication of ETBR might be suggested because of the
equal afﬁnity of this receptor for the three ET isoforms [41]. In contrast,
HGF showed a stimulatory effect on TOPFLASHLuc activity (Fig. 5D).
TOPFLASHLuc activity gives an idea of the functional role of β-catenin-
mediated transactivation of theWnt pathway. TOPFLASH containsmul-
tiple TCF/LEF consensus sites upstream from a c-fosminimal promoter,
driving luciferase expression. The binding of β-catenin to TCF and its
translocation to the nucleus induces the luciferase activity [13,42].
ET-1 enhanced the steady state protein level of MMP 9, and Runx2-
dominant negative prevented this effect (Fig. 5E).
The data obtained in in vitro experiments with 1833-bonemetastatic
clone, and some conclusions are summarized in Fig. 5F. Hypoxia and
TGFβ stimulated ET-1-ETAR axis. The latter pathway activated Runx2,
while Wnt/β-catenin activity was reduced. As a consequence, genes for
osteomimicry such asMMP 9 could be expressed. In contrast, HGF stim-
ulatedWnt/β-catenin pathway, and possibly the couple RANKL/RANK in
osteoclasts [43]. HGF might counteract the effect of ET-1 on Runx2
transactivation.
3.5. ET-1, ETAR and ETBR expression in pair-matched primary breast
carcinoma and bone metastasis
The in vitro studies were performed with 1833 clone, derived from
MDA-MB231 triple-negative breast cancer cells [44]. Among breast can-
cers, only 10–15% is categorized as triple-negative [45].
A poorly invasive breast carcinoma cell line MCF-7, ERα and PR pos-
itive and HER2 negative [43], secretes low levels of ET-1 [46]. ET-1 and
HGF stimulated MCF-7 cell invasiveness (Supplementary Fig. 2). We ex-
tended ourmolecular study on ET-1 axis to human specimens of invasive
ductal breast carcinoma positive for ERα (85–95%) and PR (23–37%),
and negative for HER2. This type of carcinoma has an incidence of
more than 80% [45]. Five biopsies from ERα/PR positive and HER2 nega-
tive invasive breast carcinomas of middle degree of differentiation, pair
matched with bone metastases were examined. We also studied dys-
plastic lesions within breast-carcinoma tissue (Fig. 6). Bone metastases,
collected about ten years after the patients completed the therapeutic
treatments, were overt lesions. Until now, molecular studies of ET-1
axis during progression from preneoplastic lesions to bone metastasis
have never been performed. Representative immunohistochemical re-
sults are shown in Fig. 6A, and the semiquantitative evaluation of the
data is reported in Table 1.
Bone metastases were positive for ET-1 = ETAR N ETBR. A very
strong ET-1 signal occurred throughout the cell, including the nuclei;
ETARwas remarkably present at the plasma-membrane level and slight-
ly in nuclei; ETBR was observed in the cytosol at a very low level. Ductal
820 P. Bendinelli et al. / Biochimica et Biophysica Acta 1843 (2014) 815–826carcinoma resulted similarly positive for ET-1, ETAR and ETBR. Positive
immunostaining was observed in the stroma of ETRs positive carcino-
mas, consistentwith the literature [47]. Itwas really interesting as a pre-
dictive index that ET-1-ETAR expression strongly increased fromnormal
ductal epithelium to carcinoma in situ. ET-1 and ETAR were absent or
very low in normal tissue adjacent to carcinoma, in agreement with
the fact that they are rarely detected in non-neoplastic tissues [48].
Negative controls, performed without speciﬁc antibodies, did not
stain positively (Fig. 6B).Fig. 3. In 1833 and MDA-MB231 cells, Endothelin-1 differently affected cell invasiveness and E
assay. We counted the invading cells on the lower side of the membrane after staining. The ima
at the bottom are themeans ± S.E. of the cells counted in ten selected ﬁelds for three independ
pared from cells exposed to Endothelin-1 (50 ng/ml) were analyzed byWestern blot. Densitom
each lane. For ETAR, themolecular weight for the band corresponding to basal amino acid seque
indicate the fold-variations versus 1833 starvation (st) value taken as 1. Vinculinwasused for no
were exposed to Endothelin-1 for 24 h on coverslips, andwere probedwith anti-Vimentin (gree
(blue). The third panel for each antibody shows the merge. The images are taken at 400× magFor comparison, biopsies from three ductal breast carcinomas ERα
and PR negative were studied for ET-1 axis (Supplementary Fig. 3). In
this type of carcinoma, only ETAR was slightly expressed (+, semiquan-
titative evaluation), in agreementwith steroid-hormone receptor status
[28].
Thus, the ET-1 axismight be a promising anti-metastatic therapeutic
target for aggressive breast carcinoma, positive for steroid hormone
receptors, in the absence of an effective adjuvant therapy hampering
delayed secondary outgrowth in the complex bone microenvironment.MT/MET gene expression. (A) Endothelin-1 treated cells were used for Matrigel invasion
ges are taken at 200× magniﬁcation. Representative images are shown, and the numbers
ent experiments. *P b 0.05 and **P b 0.005 versus starvation value. (B) Total extracts pre-
etric evaluationwas performed, taking into consideration all the immunoreactive bands in
ncewas 49 kDa in 1833 cells, and 50 kDa inMDA-MB231 cells. The numbers at the bottom
rmalization. The images are representative of three independent experiments. (C) The cells
n), anti-Snail (red) or anti-E-cadherin (red) antibodies. The nuclei were stainedwith DAPI
niﬁcation, and are representative of experiments performed in triplicate.
Fig. 4. Regulation of Endothelin-1 expression. (A) Structure of entire human Endothelin-1 promoter: the position of the consensus sites for transcription factors is indicated. Minimal pro-
moter constructs (−650/+173),without orwith 3′-UTR linkeddownstream, are also shown. (B, C) Cellswere transiently transfectedwith Endothelin-1 promoter constructs, and exposed
to the various treatments. The histograms indicate the absolute values of Fireﬂy/Renilla luciferase activity ratios. The data are the means ± S.E. of three independent experiments per-
formed in triplicate. *P b 0.05, **P b 0.005, ***P b 0.001 versus respective value of transfected cells under starvation. (D) The cells were transiently transfected with the promoter con-
structs driven by multimers of transcription factor binding sites, and exposed to the various treatments. The histograms indicate the fold-variations versus the respective value of
transfected cells under starvation, taken as 1. The data are the means ± S.E. of three independent experiments performed in triplicate. *P b 0.05, **P b 0.005, ***P b 0.001 versus the
respective value of transfected cells under starvation.
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Thebonemetastasismicroenvironment provides a dynamic network
of stimuli and molecular signals responsible for the functional interac-
tion of neoplastic cells with stroma, which includes host-tissue cells
and the surrounding extracellular matrix (ECM). The cellular compo-
nents, i.e. bone marrow stem cells, osteoclasts and osteoblasts, in addi-
tion to the physical features and the numerous biological stimuli from
metastasis and stroma enable homing, survival/proliferation and
osteolysis [49]. Hypoxia contributes to osteolytic bone metastasis
[22,50].
In the present paper, we show that microenvironmental stimuli like
HGF, TGFβ and hypoxia differently inﬂuenced the ET-1 axis in bone
metastatic cells. These are new data deepening the pivotal role of ET-1
and its receptors in osteolytic bone metastatic process, while before
ET-1 axis had been considered important for osteoblastic bonemetasta-
sis [50]. As component of an interactive network of signaling pathways,
ET-1 might be important for bone tropism by triggering osteomimicry,
and for colonization by regulating invasive phenotype and MET versus
EMT. Our principal ﬁndings obtained in vitro and in human specimens
impact on the ﬁeld of osteolytic metastasis showing metastatic adapt-
ability to bone microenvironment.
Ductal breast carcinomas are highly heterogeneous, and the type
most aggressive, even if rare, is triple negative when tested for ER/PR
and HER2. A correspondence may exist with invasive MDA-MB231
cell line. The 1833 bone metastatic clone derives from MDA-MB231
cells [12]. The MCF-7 cell line is, instead, ER/PR positive as the pair-
matched human samples of primary carcinoma and metastasis. These
comparative experiments were performed to evidence in the cell lines
characteristicmolecular events affected bymicroenvironmental stimuli,
to explain bone tropism andmetastasis engraftment in vivo and to iden-
tify predictive markers.
First of all, in response to ET-1 parental MDA-MB231 cells had EMT
phenotype and mesenchymal shape, differing from 1833 clone, which
showedMET phenotype and epithelial shape. These ﬁndings are consis-
tent with the invasive properties of primary carcinoma that are neces-
sary to penetrate the basement membrane and the surrounding
tissues, and to form foci in distant organs. In contrast, bone colonization
is related to the constitution of ametastatic tissue [51]. In support of the
signiﬁcance of ET-1 axis in bone metastasis, 1833 cells exposed to ET-1
expressed E-cadherin, the principal adhesive intercellular molecule,
while N-cadherin, Vimentin, Snail and MMP 2 were reduced. Enhance-
ments of ET-1 release and ET-1-ETAR expression were observed in re-
sponse to TGFβ or hypoxia. Autocrine and paracrine ET-1 seemed
similarly implicated in the impairment of metastatic cell invasiveness,
possibly relevant for engraftment after arrival in the secondary bone
site.
In contrast, MDA-MB231 cells exposed to ET-1 showed an enhanced
motile phenotype with MMP 2 accumulation without E-cadherin ex-
pression, and the mesenchymal markers N-cadherin, Vimentin and
Snail were sensibly increased. Since ET-1 expression and release were
stimulated byHGF and TGFβ, we suggest that EMTproperties of invasive
MDA-MB231 cells were affected by the network of microenvironmental
stimuli met during diffusion.
Second, we showed that in 1833 cells HGF triggeredmolecular events
different from thosedue to TGFβ/hypoxia andET-1, indicating thatmicro-
environmental stimuli are variously implicated in engraftment and/orFig. 5. Effects of Endothelin-1 and HGF on the activities of Runx2 andWnt/β-catenin pathways.
to Endothelin-1 in the presence or the absence of BQ123, or to themicroenvironmental stimuli
data are the means ± S.E. of three independent experiments performed in triplicate. *P b 0.05
ΔP b 0.05 and ΔΔΔP b 0.001 versus the value of Endothelin-1 exposed cells. (E) Total extracts p
Runx2 dominant negative (ΔRunx2) were analyzed by Western blot. The numbers at the bott
for normalization. The images are representative of three independent experiments. (F) Schem
to microenvironmental stimuli, and some interconnected pathways important for osteolytic mcolonization. The possible function of HGF in bone metastasis warrants
a wider discussion, taking into account that HGF negatively regulated
ET-1 axis in 1833 cells but not in MDA-MB231 cells.
Some regulatory mechanisms involved in ET-1 production in 1833
cells were examined because of the possible therapeutic implication.
ET-1-ETAR axis activates several coordinated and interconnected signal-
ing pathways and transcription factors, that also rely on interactions
with the metastasis microenvironment. Novel agents are designed to
efﬁciently disrupt the interactions betweenmetastasis and bonemicro-
environment niche [50]. HGF reduced HRELuc activity, an index of HIF-
1-mediated transactivation. TheHGF-inhibitory effect occurred through
a HIF-1 consensus site (CGTT),−118 bp upstream from the transcrip-
tion start site of the ET-1 minimal promoter [52]. Opposite to the
negative response to HGF, this HIF-1 consensus sequence appeared im-
portant for the stimulatory response to hypoxia enhancing ET-1 expres-
sion in metastatic cells.
The premetastatic niche hospitable for bone metastasis might be
hypoxic, possibly affecting ET-1 expression and stabilization through
epigenetic mechanism(s) [27,53]. Altogether, regulation of ET-1 in
1833 cells under hypoxia was complex, and included the 3′-UTR
destabilizing effect on the transcript. TGFβ and hypoxia transactivated
ET-1 through a cooperation of transcription-factor binding sites present
on entire and minimal promoters, respectively, and ET-1 protein levels
consistently augmented. We cannot exclude a role of ETAR internaliza-
tion and recycling in the control of ET-1 signaling in 1833 cells. In fact,
the ETAR receptor was present intracellularly under basal conditions,
and the nuclear expression increased after the studied stimuli. For the
ﬁrst time we showed under TGFβ treatment nuclear and perinuclear
localization of ETAR, that can be attributed to ligand-dependent translo-
cation from plasma membrane and/or de novo synthesis. G-protein-
coupled receptors at the nuclear and perinuclear level may activate
speciﬁc signaling pathways, and receptor-ligand complexes dissociate
very slowly following internalization [36].
The ability of ET-1 gene to respond to various biological and
physical stimuli, through different molecular transcriptional and
post-transcriptional, as well as genetic and epigenetic mechanisms,
seems essential for spatial, temporal and quantitative inﬂuence on
aberrant ET-1 expression conﬁrming the function of the axis in
bone metastasis colonization [54].
Of great importance for bone tropism and osteolytic metastasis,
ET-1 and HGF oppositely affected Runx2-transcription factor and
Wnt/β-catenin pathway. ET-1 activated Runx2 enhancing the ex-
pression of the target-gene MMP 9 in metastatic cells, that acquired
an osteomimetic phenotype. Thus, skeletal metastasis might substi-
tute for the early osteoblastic population in activating osteoclasts via
RANKL/RANK couple. Stimulation of osteoblasts can paradoxically
increase osteoclast function [43]. One of the ﬁrst steps involved in
the formation of the tumor microenvironment is remodeling of
ECM viaMMPs. This is considered an inciting event in the formation
of the dynamic network that supports metastatic tumor outgrowth.
In 1833 cells, MMP 9 and 2 showed opposite patterns in response to
ET-1 of paracrine (bone) [48] and/or autocrine (bone metastasis)
origin.
We cannot exclude that the interactive network consisting in HGF-
dependent Wnt/β-catenin pathway, conferring anoikis resistance via
Src activity [10,13,55], as well as the ET-1-dependent osteomimicry,
contributed to establishment of bone metastasis. In agreement with(A–D) The cells were transiently transfectedwith Runx2Luc or TOPFLASHLuc and exposed
. The histograms indicate the absolute values of Fireﬂy/Renilla luciferase activity ratios. The
, **P b 0.005, ***P b 0.001 versus the respective value of transfected cells under starvation;
repared from cells exposed to Endothelin-1 (50 ng/ml) in the presence or the absence of
om indicate the fold-variations versus starvation (st) value taken as 1. Vinculin was used
e summarizing in 1833 cells the results on ET-1 axis expression and function in response
etastasis.
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oblast phenotype and osteomimicry-related breast cancer metastatic
activity [56]. Future perspectiveswould include combinatorial therapies
targeting autocrine ET-1 in metastasis (osteomimetic phenotype) andFig. 6. Immunohistochemical analysis of ET-1 axis in pair-matched breast carcinoma and bonem
middle degree of differentiation (n = 5), pairmatchedwithbonemetastases (n = 5), and represe
for each specimen, and similar results were obtained from all the repeated observations. Antibody
were performed in the absence of speciﬁc antibodies.Wnt/β-catenin pathway downstream of HGF and Src activity, valid to
block escape strategies of metastasis [14].
Bone resorption results in the release of growth factors, whichmight
unintentionally increase the formation of skeletal metastasis byetastasis. (A)We analyzed ERα/PR positive and HER2 negative invasive breast carcinomas of
ntative images are shown. Insets:magniﬁcation of details. Five serial sectionswere examined
dilutions: anti-ET-1 (1:50); anti-ETAR (4 μg/ml); anti-ETBR (1 μg/ml). (B) Negative controls
Table 1
Semiquantitative evaluation of immunohistochemical data for Endothelin-1, ETAR and ETBR expression, and their intracellular distribution in the different preneoplastic and neoplastic
lesions. Five serial sections from ﬁve specimens from each disease stage and for each immunostaining were quantiﬁed.
Endothelin-1 staining ETAR staining ETBR staining
Bone metastasis +++
throughout the cell
+++ +
cytosol, plasma membrane; nuclei
+/−
cytosol
Ductal carcinoma ++
throughout the cell
++ +
plasma membrane; cytosol, nuclei
++
cytosol, plasma membrane
Carcinoma in situ +++
throughout the cell
+++
cytosol, plasma membrane
++
cytosol, plasma membrane
Adjacent normal tissue – +
plasma membrane
+
cytosol, plasma membrane
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ple [57], which seemed to counteract the functions of ET-1, important
for osteomimetic and MET phenotypes, as well as of TGFβ. It is known
that TGFβ plays a dual role: tumor suppressor in earlier stages but
promoter of cancer progression in later stages of the disease. TGFβ is fre-
quently overexpressed in breast cancer, correlatingwith poor prognosis
and metastasis [58].
Temporal intervention and reciprocal regulation of the different stim-
uli may be of high signiﬁcance for the deﬁnitive balance of molecular and
cellular events determining bonemetastasis fate. HGF rapidly available in
blood and bonemicroenvironment [13], is known to exert anti-apoptotic
functions [14,57]. Anoikis resistance of cancer cells plays a pleiotropic role
during several of the steps of metastatic dissemination, and it is truly es-
sential to obtain successful metastasis [41]. Thus, systemic and local HGF
pools might protect metastatic cells from anoikis, counteracting the ET-1
effect in a temporal sequence. Metastatic cells in the secondary bone site,
ﬁrst exploit resistance to anoikis signaling related to EMTphenotype, and,
then,METphenotypewould occur only after the shift towards the expres-
sion of a new set of integrins, that correctly bind the ECM proteins on the
new site [55]. Metastatic colonization and the consequent de novo
achievement of an epithelial phenotype through MET may be associated
with sensitivity to anoikis as well [55]. ET-1 dependent osteomimetic
phenotype would contribute instead to engraftment and successful
bone metastasis.
Third, coherent observations were obtained with human samples of
bone metastases, pair-matched with primary breast carcinomas. These
data supported our in vitro ﬁndings in MCF-7, MDA-MB231 and 1833
cell lines, endowed with different invasive and bone metastatic poten-
tial, and correlated the molecular aspects of ET-1 axis with cancer pro-
gression. Until now, molecular studies of ET-1 axis during progression
from preneoplastic lesions to bone metastasis have never been per-
formed. However, generalization of our results may be limited by the
relatively small sample size, even if their importance relies essentially
on pair-matching of primary carcinoma and metastasis. This limitation
notwithstanding, our data could offer a valid background for further
conﬁrmatory research.
In conclusion, ET-1/ETAR/ETBR seemed to be potential markers of
premalignant-breast lesions, useful as predictive indicators of aggres-
sive behavior and bone metastatic capacity. The expression of the
three components of the ET-1 axis was higher in the carcinoma in situ
than in invasive breast carcinoma ERα/PR positive and HER2 negative.
ET-1 and ETAR were remarkably expressed in bone metastasis,
conﬁrming their critical role for skeletal colonization in humans. In the
metastasis specimens, as well as in the carcinoma in situ, ET-1-ETAR
were present at plasma membrane, but also in nuclei, indicating that
ET-1 might also act intracellularly in humans.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2013.12.015.
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